Joselle Cook
@JoselleCookMD
Followers
1K
Following
3K
Media
64
Statuses
521
Hematologist @Mayoclinic Rochester | proud #uwigrad |#Downstate-alum. Dyspro #MM , Precursor Conditions
Minnesota, USA
Joined September 2017
Register and attend: The 2nd Annual Kyle Barlogie Plasma Cell Disorders Symposium featuring top myeloma experts from @MayoClinic and @MSKCancerCenter Info and registration link: https://t.co/JaCrkR23KH
@szusmani @myelomaMD
1
7
31
If approved, patients with high risk smoldering myeloma will have a choice that can delay progression to active myeloma and highly likely to prolong life. More on the CHMP decision here: https://t.co/iZ2RmTAjJy
globenewswire.com
If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple...
2
6
21
Excellent work and an important piece of data by @dr_arewah_bohra 👏👏Translating Peripheral blood flow data into meaningful thresholds aligning with the peripheral smear-based criteria for PCL. 1.2% CPCs by flow ≈ 5% CPCs by smear @MayoMyeloma
Excited to share our recent work redefining Plasma Cell Leukemia using peripheral blood flow cytometry, now published in Leukemia. Grateful to my mentor @myelomaMD and the incredible Mayo Clinic Myeloma group @mayomyeloma @VincentRK
@zanwarsaurabh
@RifuHassanMD
1
3
10
What an incredible community for #MM patients and their families @IMFmyeloma thank you for having me
Patients and Care partners have important questions and these two #myeloma specialists have excellent answers and resources. Thank you @JoselleCookMD and Dr Sborov! @IMFmyeloma #mmsm
1
2
20
Calling all hematologists! Apply to join the dynamic ASH News Daily team, where we break down the ASH meeting into engaging and easy-to-read insights @ASH_hematology
0
2
9
The very first paper from the @iStopMM study was published in @BloodCancerJnl in 2021 and describes the design of the study. iStopMM is the first population-based MGUS screening study and a randomized trial of follow-up strategies. 📊🔬🧵👇 #iStopMM #MMsm
1
9
49
Symptoms DO matter Important publications by my friend and colleague @nadineabdal
Also out in @BloodAdvances during #ASH24 by rising 🌟 @nadineabdal and @MayoMyeloma! PROs strongly correlate with OS in #MMsm. In MVA, fatigue as prognostic for OS as FISH and ASCT 😳 Some confounders (anemia, frailty) but worth studying interventions! https://t.co/0gxOavv7EE
0
4
13
The @MayoMyeloma group #ASH24 Also missing @RahmaWarsameMD . Wilson Gonsalves. Eli Muchtar. Erin Weidmeier
The @MayoClinic myeloma group at #ASH24
@MayoMyeloma Many others are hard at work back home in Rochester, Arizona, and Florida. Moritz Binder, @MorieGertz @Rfonsi1 @ADispenzieri Suzanne Hayman et al.
0
2
12
Read ➡️ how my mentor @VincentRK persisted and collaborated in #SMM early intervention trials, culminating into the landmark AQUILA trial #ASH24 So much to learn from his experience
AQUILA trial for high risk smoldering myeloma published in @NEJM today. @thanosdimop Personally for me, it is a huge milestone along 25 years of work that started in 1998. #ASH24 #ASH24VR This story below may help those interested in a clinical trialist career. 1/
0
4
14
Best things happen with best partners @JoselleCookMD #ASH24
Expert moderation in action! Kudos to @JoselleCookMD @hiragss for a great session on T-cell engager RWE in myeloma @UIowaCancer #ASH24
2
3
16
Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24
@thanosdimop @NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial https://t.co/NMnjBytzQT Slides in thread
17
126
344
A snapshot of the energy and camaraderie fueling #ASH24
@AjHematology @ASH_hematology @VincentRK @n_gangat
1
1
11
The unexpected withdrawal of #VOXELOTOR for sickle cell disease shocked everyone. 👉🏾MUST-READ interview w/ experts @DrAlexisThompsn @jstrous1 🚩attend Monday 1030am Room 33 convention center @ASH_hematology
https://t.co/Sq4XsxYSID
0
4
16
AL, ATTRwt and ATTRv amyloidosis each tell a different story #ASH24 #amyloidosis
#ASHKudos to all in the ASH Amyloid Guidelines panel for taking on the rigorous scoping analysis
#ASH24 #mmsm @ASH_hematology Amyloid guidelines session @JoselleCookMD Very nice slides on earliest symptoms, most frequently reported symptoms, and symptoms that are oven under looked
0
4
6
Thanks Samer for sharing! The scoping undertaking by the ASH Amyloid Guideline Panel really differentiated the 🚩red flags, early signs and most frequent patient reports for the various forms of #amyloidosis . 🚨Earlier suspicion, earlier diagnosis #ASH24
#ASH24 #mmsm @ASH_hematology Amyloid guidelines session @JoselleCookMD Nice summary slides on different symptoms between AL and ATTR amyloid
0
4
10
Important slide by @JoselleCookMD on clinical presentation of AL vs ATTR #Amyloidosis! Interesting to see more hypotension in AL. Gradual drop in BP and patients coming off anti-HTN is a red flag symptom of AL in patients with MGUS/SMM! #ASH24
1
18
37
Read ASHNewsDaily @ckbrierly article for the scientific symposium you shouldn’t miss today and tomorrow. #ASH24 @JuliPerezBot @ASH_hematology
0
1
8
👏 👏 This is the type of #ASH24 policy we need!! I mainly worry about Duffy null status preventing Black & Arab heritage patients with #MMsm from getting correct lenalidomide & pomalidomide dosing... But the implications are so much broader than that!
#ASH24 news: Universal Duffy Testing is Likely Cost Effective for U.S. Population https://t.co/255tjgOT0W
0
4
8
Thank you Samer! These career development grants are so important for supporting junior faculty! Very appreciative to #MMRF @HJChoMDPhD1 @VincentRK . Look out for prelim results #ASH25 😊
Pleased to see @JoselleCookMD @EdenBiltibo @theMMRF #mmsm #ASH24 achievements of getting MMRF 2023 Scholar Grant Awardees
0
2
10